ArticlePloS one2013
Newcastle disease virus fusion protein is the major contributor to protective immunity of genotype-matched vaccine.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 81 citations in OpenAlex.
- Article
- The production of Newcastle disease virus-like particles inFrontiers in plant science · 2023Article
- Genetic diversity of Newcastle disease viruses circulating in wild and synanthropic birds in Ukraine between 2006 and 2015.Frontiers in veterinary science · 2023Article
- Article
- Article
- Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.BMC cancer · 2021Article
- Phylogenetic relationship and genotype variation of six Newcastle disease viruses isolated from duck in Indonesia.Veterinary world · 2021Article
- Article
- The Immunogenicity of a Novel Chimeric Hemagglutinin-Neuraminidase-Fusion Antigen from Newcastle Disease Virus by Oral Delivery of Transgenic Canola Seeds to Chickens.Molecular biotechnology · 2020Article
- Article
- Article
- Reverse Genetics Assembly of Newcastle Disease Virus Genome Template Using Asis-Sal-Pac BioBrick Strategy.Biological procedures online · 2020Article
- Retraction: Newcastle disease virus fusion protein is the major contributor to protective immunity of genotype-matched vaccine.PloS one · 2020Article
- Article
- Evaluation of a fusion gene-based DNA prime-protein boost vaccination strategy against Newcastle disease virus.Tropical animal health and production · 2019Article
- Article
- Viral infection detection using metagenomics technology in six poultry farms of eastern China.PloS one · 2019Article
- Newcastle disease sero and viro-prevalence in rural poultry in Chittagong, Bangladesh.Preventive veterinary medicine · 2018Article
- Adaptation of Newcastle Disease Virus (NDV) in Feral Birds and their Potential Role in Interspecies Transmission.The open virology journal · 2018Review
- Molecular Characterization of Newcastle Disease Virus from Backyard Poultry Farms and Live Bird Markets in Kenya.International journal of microbiology · 2018Article
Corrections and comments
- Retraction · 2020-12-14Concerns/Issues about Data · Duplication of/in Image · Manipulation of Images · Original Data and/or Images not Provided and/or not Available · · Shin Hee Kim has ORI finding of misconduct; see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220845/;
- Commented on by
- Retracted
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Virulent strains of Newcastle disease virus (NDV) can cause devastating disease in chickens worldwide. Although the current vaccines are substantially effective, they do not completely prevent infection, virus shedding and disease. To produce genotype-matched vaccines, a full-genome reverse genetics system has been used to generate a recombinant virus in which the F protein cleavage site has been changed to that of avirulent vaccine virus. In the other strategy, the vaccines have been generated by replacing the F and HN genes of a commercial vaccine strain with those from a genotype-matched virus. However, the protective efficacy of a chimeric virus vaccine has not been directly compared with that of a full-genome virus vaccine developed by reverse genetics. Therefore, in this study, we evaluated the protective efficacy of genotype VII matched chimeric vaccines by generating three recombinant viruses based on avirulent LaSota (genotype II) strain in which the open reading frames (ORFs) encoding the F and HN proteins were replaced, individually or together, with those of the circulating and highly virulent Indonesian NDV strain Ban/010. The cleavage site of the Ban/010 F protein was mutated to the avirulent motif found in strain LaSota. In vitro growth characteristics and a pathogenicity test indicated that all three chimeric viruses retained the highly attenuated phenotype of the parental viruses. Immunization of chickens with chimeric and full-length genome VII vaccines followed by challenge with virulent Ban/010 or Texas GB (genotype II) virus demonstrated protection against clinical disease and death. However, only those chickens immunized with chimeric rLaSota expressing the F or F plus HN proteins of the Indonesian strain were efficiently protected against shedding of Ban/010 virus. Our findings showed that genotype-matched vaccines can provide protection to chickens by efficiently preventing spread of virus, primarily due to the F protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.